Biontech SE
BNTX106.620USD
+1.080+1.02%
Fechamento 02/06, 16:00（ET）Cotações atrasadas em 15 min
25.64BValor de mercado
PerdaP/L TTM
Mais detalhes de Biontech SE Empresa
BioNTech SE is a Germany-based clinical-stage biotechnology company. The Company focuses on patient-specific immunotherapies for the treatment of cancer and other serious diseases. The Company is providing technologies including mRNA-based therapies, cell therapies, small molecules and antibodies, which can be utilized for specific purposes or can be even combined with each other in a synergistic manner. It also develops a broad product pipeline using different scientific approaches and technology platforms, including individualized mRNA-based product candidates, chimeric antigen receptor T-cells, checkpoint immunomodulators, targeted cancer antibodies and small molecules. In addition, the Company offers diagnostic products and drug discovery services for other therapeutic areas, including infectious diseases, allergies and autoimmune disorders.
Informações de Biontech SE
Código da empresaBNTX
Nome da EmpresaBiontech SE
Data de listagemOct 10, 2019
CEOSahin (Ugur)
Número de funcionários6772
Tipo de títulosDepository Receipt
Fim do ano fiscalOct 10
EndereçoAn der Goldgrube 12
CidadeMAINZ
Bolsa de valoresNASDAQ OMX - NASDAQ BASIC
PaísGermany
Código postal55131
Telefone4949613190840
Sitehttps://www.biontech.com/
Código da empresaBNTX
Data de listagemOct 10, 2019
CEOSahin (Ugur)
Executivos da empresa Biontech SE
Nome
Nome/Posição
Posição
Ações detidas
Variação
Dr. Sierk Poetting, Ph.D.
Dr. Sierk Poetting, Ph.D.
Chief Operating Officer, Member of the Management Board
Chief Operating Officer, Member of the Management Board
767.54K
+12755.00%
Dr. Ulrich Wandschneider, Ph.D.
Dr. Ulrich Wandschneider, Ph.D.
Independent Deputy Chairman of the Supervisory Board
Independent Deputy Chairman of the Supervisory Board
1.48K
--
Mr. James Ryan
Mr. James Ryan
Member of the Management Board, Chief Legal Officer
Member of the Management Board, Chief Legal Officer
790.00
+790.00%
Prof. Rudolf Staudigl, Ph.D.
Prof. Rudolf Staudigl, Ph.D.
Independent Member of the Supervisory Board
Independent Member of the Supervisory Board
400.00
--
Prof. Anja Morawietz, Ph.D.
Prof. Anja Morawietz, Ph.D.
Independent Member of the Supervisory Board
Independent Member of the Supervisory Board
240.00
--
Dr. Oezlem Tuereci, M.D.
Dr. Oezlem Tuereci, M.D.
Chief Medical Office, Member of the Management Board
Chief Medical Office, Member of the Management Board
--
--
Mr. Helmut Jeggle
Mr. Helmut Jeggle
Independent Chairman of the Supervisory Board
Independent Chairman of the Supervisory Board
--
--
Mr. Michael Motschmann
Mr. Michael Motschmann
Independent Member of the Supervisory Board
Independent Member of the Supervisory Board
--
--
Mr. Michael Horowicz
Mr. Michael Horowicz
Director, Investor Relations
Director, Investor Relations
--
--
Ms. Annemarie Hanekamp
Ms. Annemarie Hanekamp
Member of the Management Board, Chief Commercial Officer
Member of the Management Board, Chief Commercial Officer
--
--
Ver Mais
Nome
Nome/Posição
Posição
Ações detidas
Variação
Dr. Sierk Poetting, Ph.D.
Dr. Sierk Poetting, Ph.D.
Chief Operating Officer, Member of the Management Board
Chief Operating Officer, Member of the Management Board
767.54K
+12755.00%
Dr. Ulrich Wandschneider, Ph.D.
Dr. Ulrich Wandschneider, Ph.D.
Independent Deputy Chairman of the Supervisory Board
Independent Deputy Chairman of the Supervisory Board
1.48K
--
Mr. James Ryan
Mr. James Ryan
Member of the Management Board, Chief Legal Officer
Member of the Management Board, Chief Legal Officer
790.00
+790.00%
Prof. Rudolf Staudigl, Ph.D.
Prof. Rudolf Staudigl, Ph.D.
Independent Member of the Supervisory Board
Independent Member of the Supervisory Board
400.00
--
Prof. Anja Morawietz, Ph.D.
Prof. Anja Morawietz, Ph.D.
Independent Member of the Supervisory Board
Independent Member of the Supervisory Board
240.00
--
Dr. Oezlem Tuereci, M.D.
Dr. Oezlem Tuereci, M.D.
Chief Medical Office, Member of the Management Board
Chief Medical Office, Member of the Management Board
--
--
Detalhamento da receita
Moeda: USDAtualizado em: qua, 12 de mar
Moeda: USDAtualizado em: qua, 12 de mar
FY2019
FY2018
FY2017
Por EmpresaUSD
Nome
Receita
Proporção
Collaboration Revenue
84.43M
77.75%
Revenues from Other Sales Transactions
24.16M
22.25%
Os dados relevantes ainda não foram divulgados pela empresa.
Por Empresa
Por Região
Por EmpresaUSD
Nome
Receita
Proporção
Collaboration Revenue
84.43M
77.75%
Revenues from Other Sales Transactions
24.16M
22.25%
Distribuição de ações
Atualizado em: seg, 2 de fev
Atualizado em: seg, 2 de fev
Investidores
Tipos de investidores
Investidores
Investidores
Proporção
AT Impf GmbH
39.32%
Medine GmbH
15.49%
Fidelity Management & Research Company LLC
1.92%
T. Rowe Price Investment Management, Inc.
1.87%
Flossbach von Storch AG
1.62%
Outro
39.78%
Investidores
Investidores
Proporção
AT Impf GmbH
39.32%
Medine GmbH
15.49%
Fidelity Management & Research Company LLC
1.92%
T. Rowe Price Investment Management, Inc.
1.87%
Flossbach von Storch AG
1.62%
Outro
39.78%
Tipos de investidores
Investidores
Proporção
Corporation
55.45%
Investment Advisor
11.60%
Investment Advisor/Hedge Fund
3.54%
Individual Investor
1.95%
Research Firm
1.11%
Hedge Fund
0.98%
Sovereign Wealth Fund
0.71%
Pension Fund
0.16%
Bank and Trust
0.14%
Outro
24.35%
Participação acionária institucional
Atualizado em: seg, 8 de dez
Atualizado em: seg, 8 de dez
Período do relatório
N.º de instituições
Ações detidas
Proporção
Variação
2025Q4
771
54.72M
25.43%
-10.33K
2025Q3
808
54.84M
25.69%
-1.45M
2025Q2
821
56.21M
24.34%
+2.26M
2025Q1
832
54.17M
23.64%
-2.66M
2024Q4
855
52.85M
22.63%
+3.24M
2024Q3
827
49.68M
20.44%
+4.23M
2024Q2
801
45.24M
20.73%
+361.30K
2024Q1
817
44.34M
21.44%
-6.62M
2023Q4
879
44.00M
20.40%
+3.38M
2023Q3
904
40.73M
20.46%
-291.47K
Ver Mais
Atividade dos acionistas
Nome
Ações detidas
Proporção
Variação
Var. %
Data
AT Impf GmbH
101.85M
40.33%
-636.54K
-0.62%
Dec 31, 2024
Medine GmbH
40.13M
15.89%
-304.48K
-0.75%
Mar 31, 2025
Fidelity Management & Research Company LLC
4.98M
1.97%
-2.00M
-28.65%
Sep 30, 2025
T. Rowe Price Investment Management, Inc.
4.83M
1.91%
+1.24M
+34.32%
Sep 30, 2025
Flossbach von Storch AG
4.23M
1.68%
-65.00
-0.00%
Sep 30, 2025
PRIMECAP Management Company
3.87M
1.53%
-130.70K
-3.27%
Sep 30, 2025
Dodge & Cox
3.65M
1.44%
+2.77M
+315.65%
Sep 30, 2025
Sahin (Ugur MD)
2.05M
0.81%
-724.50K
-26.11%
Mar 31, 2025
Pfizer Inc
1.66M
0.66%
-2.00M
-54.67%
Sep 30, 2025
Temasek Holdings Pte. Ltd.
1.51M
0.6%
--
--
Sep 30, 2025
Ver Mais
ETFs Relacionados
Atualizado em: sáb, 6 de dez
Atualizado em: sáb, 6 de dez
Nome
Proporção
Langar Global HealthTech ETF
4.06%
iShares Genomics Immunology and Healthcare ETF
3.6%
First Trust NYSE Arca Biotechnology Index Fund
3.42%
Global X Genomics & Biotechnology ETF
3.11%
WisdomTree BioRevolution Fund
2.74%
Franklin Genomic Advancements ETF
2.46%
VanEck Biotech ETF
2.38%
Virtus LifeSci Biotech Products ETF
1.58%
ProShares Ultra Nasdaq Biotechnology
1.02%
Invesco Nasdaq Biotechnology ETF
1.01%
Ver Mais
Langar Global HealthTech ETF
Proporção4.06%
iShares Genomics Immunology and Healthcare ETF
Proporção3.6%
First Trust NYSE Arca Biotechnology Index Fund
Proporção3.42%
Global X Genomics & Biotechnology ETF
Proporção3.11%
WisdomTree BioRevolution Fund
Proporção2.74%
Franklin Genomic Advancements ETF
Proporção2.46%
VanEck Biotech ETF
Proporção2.38%
Virtus LifeSci Biotech Products ETF
Proporção1.58%
ProShares Ultra Nasdaq Biotechnology
Proporção1.02%
Invesco Nasdaq Biotechnology ETF
Proporção1.01%
Dividendo
Um total de
0.00
USD foi distribuído em dividendos nos últimos 5 anos.
Data
Dividendo
Data de registro
Data de pagamento
Data ex-dividendo
Sem dados
Desdobramento de ações
Data
Data ex-dividendo
Tipo
Proporção
Sem dados
Data
Data ex-dividendo
Tipo
Proporção
Sem dados
